KEY FEATURES 

Therapeutic Class: Synthetic growth hormone–releasing factor (GRF) analog
Primary Indication: Reduction of excess abdominal fat in adults with HIV‑associated lipodystrophy

Mechanism of Action: Stimulates pituitary growth hormone release → increases IGF‑1 → reduces visceral adipose tissue

Clinical Benefit: Proven reduction in abdominal fat without affecting limb or subcutaneous fat distribution
Brand Names: Egrifta®, Egrifta SV®

TECHNICAL SPECIFICATIONS 

Molecular Type: Synthetic peptide (44‑amino acid analog of human GRF)
Formulation: Sterile lyophilized powder for reconstitution
Dosage strength 

Egrifta®: 1 mg and 2 mg vials
Egrifta SV®: 2 mg vials (small‑volume, more concentrated)

Administration: Daily subcutaneous injection into abdominal area

Preparation: Reconstituted with supplied sterile diluent before injection

Storage: Refrigerated at 2–8 °C; do not freeze; use reconstituted solution immediately

Regulatory Identifiers: Each vial carries an NDC code (U.S.) or equivalent international code for compliance

AVAILABLE CONFIGURATIONS 

Format and Delivery:

Lyophilized powder vials (single‑use)
Supplied with diluent for reconstitution

Concerntration and Dosage:

Standard Egrifta® vials (1 mg, 2 mg)
Egrifta SV® vials (2 mg, reduced diluent volume)

Packaging and Labeling:

Cartons containing vials + diluent

Professional labeling with regulatory compliance identifiers